Jonathan Schapiro, M.D.
Dr. Schapiro's research has focused on the causes of antiretroviral drug failure and interventions to optimize clinical care. This includes investigations of resistance and cross-resistance between protease inhibitors, the clinical utility of resistance assays and the integration of resistance assays and therapeutic drug monitoring into clinical care. In addition, he has been involved in the development of advanced interpretation systems for these assays.
Dr. Schapiro's work has focused on understanding HIV drug resistance and its clinical application. His publications have appeared in leading journals, such as the Annals of Internal Medicine and The Lancet. He is also very active in educational initiatives and is involved in numerous continuing medical education programs for AIDS-treating physicians. Dr. Schapiro served as an advisor to the U.S. Food and Drug Administration and is a member of numerous international HIV expert panels and working groups.
Dr. Schapiro has served as a consultant to or has received honoraria or research support from Abbott Laboratories, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck & Co., Inc., Monogram Biosciences, Pfizer, Roche Labs and Tibotec.